title: Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer.
abstract: To determine the efficacy of postoperative adjuvant chemotherapy with docetaxel + cisplatin + 5-fluorouracil (DCF) in lymph node metastasis-positive esophageal cancer, we retrospectively analyzed 139 patients with stage II/III (non-T4) esophageal cancer with lymph node metastasis (1-6 nodes), who did not receive preoperative treatment and underwent three-field lymph node dissection in the Juntendo University Hospital between December, 2004 and December, 2009. The tumors were histologically diagnossed as squamous cell carcinoma. The patients were divided into two groups, a surgery alone group (S group, 88 patients) and a group that received postoperative DCF therapy (DCF group, 51 patients). The disease-free and overall survival were compared between the groups and a multivariate analysis of prognostic factors was performed. The same analysis was performed for cases classified as N1 and N2, according to the TNM classification. There were no significant differences between the S and DCF groups regarding clinicopathological factors other than intramural metastasis and main tumor location. The presence of intramural metastasis, blood vessel invasion and the number of lymph nodes were identified as prognostic factors. The 5-year disease-free and overall survival were 55.8 and 57.3%, respectively, in the S group and 52.8 and 63.0%, respectively, in the DCF group. These differences were not considered to be statistically significant (P=0.789 and 0.479 for disease-free and overall survival, respectively). Although there were no significant differences in disease-free and overall survival between the S and DCF groups in N1 cases, both disease-free and overall survival were found to be better in the DCF group (54.2 and 61.4%, respectively) compared to the S group (29.6 and 28.8%, respectively) in N2 cases (P=0.029 and 0.020 for disease-free and overall survival, respectively). Therefore, postoperative adjuvant chemotherapy with DCF was shown to improve disease-free and overall survival in moderate lymph node metastasis-positive cases (N2), suggesting that the DCF regimen may be effective as postoperative adjuvant chemotherapy for patients with lymph node metastasis from esophageal cancer.
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Tadasuke
authors: T
authors: Hashiguchi
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Motomi
authors: M
authors: Nasu
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Takashi
authors: T
authors: Hashimoto
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Tetsuji
authors: T
authors: Kuniyasu
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Hirohumi
authors: H
authors: Inoue
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Noritaka
authors: N
authors: Sakai
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Kazutomo
authors: K
authors: Ouchi
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Takayuki
authors: T
authors: Amano
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Fuyumi
authors: F
authors: Isayama
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Natsumi
authors: N
authors: Tomita
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Yoshimi
authors: Y
authors: Iwanuma
authors: Cancer Treatment Center, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Masahiko
authors: M
authors: Tsurumaru
authors: Department of Esophageal and Gastroenterological Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan.
authors: Yoshiaki
authors: Y
authors: Kajiyama
keywords: docetaxel + cisplatin + 5-fluorouracil therapy; esophageal cancer; intramural metastasis; lymph node metastasis; postoperative adjuvant chemotherapy